Increasing options for the treatment of osteoporosis
- PMID: 19671654
- PMCID: PMC3901579
- DOI: 10.1056/NEJMe0905480
Increasing options for the treatment of osteoporosis
Conflict of interest statement
No potential conflict of interest relevant to this article was reported.
Comment on
-
Denosumab for prevention of fractures in postmenopausal women with osteoporosis.N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. N Engl J Med. 2009. PMID: 19671655 Clinical Trial.
-
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11. N Engl J Med. 2009. PMID: 19671656 Free PMC article. Clinical Trial.
Similar articles
-
[Innovations in the treatment of osteoporosis].Dtsch Med Wochenschr. 2011 Dec;136(48):2458-60. doi: 10.1055/s-0031-1297266. Epub 2011 Nov 22. Dtsch Med Wochenschr. 2011. PMID: 22109575 German. No abstract available.
-
Osteoporosis medications and your dental health.J Am Dent Assoc. 2011 Nov;142(11):1320. doi: 10.14219/jada.archive.2011.0119. J Am Dent Assoc. 2011. PMID: 22041419 No abstract available.
-
Denosumab (prolia) for postmenopausal osteoporosis.Med Lett Drugs Ther. 2010 Oct 18;52(1349):81-2. Med Lett Drugs Ther. 2010. PMID: 21045756 No abstract available.
-
Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Pharmacotherapy. 2011. PMID: 21923432 Review.
-
Denosumab for treatment of postmenopausal osteoporosis.Am J Health Syst Pharm. 2011 Aug 1;68(15):1409-18. doi: 10.2146/ajhp100493. Am J Health Syst Pharm. 2011. PMID: 21785030 Review.
Cited by
-
Synthetic biology-based bacterial extracellular vesicles displaying BMP-2 and CXCR4 to ameliorate osteoporosis.J Extracell Vesicles. 2024 Apr;13(4):e12429. doi: 10.1002/jev2.12429. J Extracell Vesicles. 2024. PMID: 38576241 Free PMC article.
-
Resorbable GBR Scaffolds in Oral and Maxillofacial Tissue Engineering: Design, Fabrication, and Applications.J Clin Med. 2023 Nov 7;12(22):6962. doi: 10.3390/jcm12226962. J Clin Med. 2023. PMID: 38002577 Free PMC article. Review.
-
2-NPPA Mitigates Osteoclastogenesis via Reducing TRAF6-Mediated c-fos Expression.Front Pharmacol. 2021 Jan 26;11:599081. doi: 10.3389/fphar.2020.599081. eCollection 2020. Front Pharmacol. 2021. PMID: 33574753 Free PMC article.
-
N-[2-(4-Acetyl-1-Piperazinyl)Phenyl]-2-(3-Methylphenoxy)Acetamide (NAPMA) Inhibits Osteoclast Differentiation and Protects against Ovariectomy-Induced Osteoporosis.Molecules. 2020 Oct 21;25(20):4855. doi: 10.3390/molecules25204855. Molecules. 2020. PMID: 33096734 Free PMC article.
-
Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis.Sci Rep. 2020 Jul 6;10(1):11115. doi: 10.1038/s41598-020-68037-8. Sci Rep. 2020. PMID: 32632237 Free PMC article.
References
-
- Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165–176. - PubMed
-
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756–765. - PubMed
-
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809–1822. - PubMed
-
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434–1441. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical